Chinese investors lead another monster round into this early cancer detection company

The Menlo Park company had already raised $1.2 billion; now it's adding $300 million, mainly from Chinese investors, as it aims to develop a simple blood test to discover cancers early.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.